A multicenter adaptive prospective randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (ACTIV-4C)

Brief description of study

Doctors use anticoagulation medicines, known as “blood thinners,” to lower the risk of blood clots forming in blood vessels (veins and arteries). Blood clots that form inside blood vessels can travel through the body and block the flow of blood to organs, like the brain, lungs, or heart. Blood thinners can be given in different doses. The chance of blood clots in patients who are diagnosed with COVID-19 appears to be higher than for patients who do not have COVID-19. In fact, most patients with COVID-19 who are admitted to the hospital are treated with blood thinners to prevent clots while they are in the hospital. The purpose of this study is to compare people who take a blood thinner after leaving the hospital with people who do not.


Clinical Study Identifier: s21-00140
ClinicalTrials.gov Identifier: NCT04650087
Principal Investigator: Shari Barnett Brosnahan.
Other Investigator: Sam Parnia.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.